Teenagers and Young Adults Cancer Services

NHS England | June 2019 | Teenagers and Young Adults Cancer Services

NHS England has launched a 60-day consultation to seek views on proposed changes to teenager and young adult’s cancer services. These are used by teenagers and young people aged between 16 up to the day before their 25th birthday. In some cases, and with the agreement of Children’s Cancer Services, they may also treat teenagers from the age of 13.

The aim of the service specifications is to improve the outcomes and experience of teenagers and young adults with cancer.

This consultation guide sets out:

  • How care is currently provided.
  • The proposed changes and reasons for these.
  • How the proposed changes will be implemented

The consultation is open until 4 August 2019

Full details are available from NHS England 

Related:

NHS England The UK should stop obsessing over GDP. Wellbeing is more telling

[NHS England Consultation] Children’s Cancer Services

NHS England | June 2019 |Children’s Cancer Services

NHS England has launched a 60-day consultation to seek views on proposed changes to children’s cancer services. These are used by children aged between 0 and 16. In some cases, and with the agreement of Teenage and Young Adult’s Cancer Services, they may also treat teenagers up to the age of 18.

The aim of the service specifications is to improve the outcomes and experience of children and young people with cancer.

This consultation guide sets out:

  • How care is currently provided.
  • The proposed changes and reasons for these.
  • How the proposed changes will be implemented.
  • The consultation has been open from Wednesday 5 June and will run until Sunday 4 August 2019

See also:

NHS England blog 

(Interim Report) Independent Review of National Cancer Screening Programmes in England

NHS England | May 2019 | Independent Review of National Cancer Screening Programmes in England

This interim report sets out emerging findings of Professor Sir Mike Richard’s review of national cancer screening programmes in England to date.  The final report and recommendations will be published later this year. 

Independent review of national cancer screening programmes in England -Interim report of emerging findings: Professor Sir Mike Richards

Full information from NHS England

In the news:

BBC News ‘Cancer screening should be as easy as booking a flight’

 

18F-fluorodeoxyglucose (FDG) positron emission tomography-computed-tomography (PET CT) as part of radical radiotherapy treatment planning for oesophageal cancer (all ages)

NHS England | April 2019 | 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed-tomography (PET CT) as part of radical radiotherapy treatment planning for oesophageal cancer (all ages)

NHS England will not routinely commission 18F-FDG-PET CT as part of radical radiotherapy treatment planning for oesophageal cancer in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources (Source: NHS England).

Further details including the evidence review, evidence report and clinical panel report are available from NHS England.

Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages)

NHS England | April 2019 | Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages)

NHS England have released a  policystatement to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours (all ages).

Policy Statement: Pazopanib for inoperable and metastatic malignant granular cell tumour

Pazopanib for inoperable and metastatic malignant granular cell tumour: Engagement Report

Pazopanib for inoperable and metastatic malignant granular cell tumour: CPAG Summary Report

Pazopanib for inoperable and metastatic malignant granular cell tumour: Clinical Panel Report

Waiting times for suspected and diagnosed cancer patients for February 2019

NHS England | | April 2019 | Waiting times for suspected and diagnosed cancer patients for February 2019

These reports present the validated results of the monitoring of waiting times for cancer services in England and the information on the number of people who attended outpatient appointments within two weeks of an urgent referral by their GP for suspected cancer or breast symptoms and, for patients with cancer, on the numbers who started treatment within 31 and 62 days are included for each organisation. The numbers who started some types of subsequent treatments within 31 days are also given for each organisation. Numbers of patients who were not seen or treated within the specified times are also included (Source: NHS England).

room-44085_640.png

Waiting times for suspected and diagnosed cancer patients for February 2019

Improving patient experience through stratification of the prostate cancer follow up pathway

Atlas of Shared Learning | March 2019| Improving patient experience through stratification of the prostate cancer follow up pathway

A recent addition to NHS England’s Atlas of Shared Learning is a case study that comes from nurses in the Urology Unit at The Royal Marsden NHS Foundation Trust who led the development and implementation of a new prostate cancer follow-up pathway. This pathway has significantly improved patient outcomes, experience and use of resources locally (Source: NHS England).

Read the case study at NHS England